TrialThe Lancet. Oncology2024

Completion axillary lymph node dissection for the identification of pN2-3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial.

Jana de Boniface et al.PubMed ↗Publisher ↗

No numbers read from the abstract.